Repurposing of the epidermal growth factor

This article deals with repurposing of the epidermal growth factor (EGF) to the treatment of diabetic foot ulcers (DFU) grades III and IV, according to the Wagner scale. The design of a repurposing commercial strategy is described in this document as a contribution to a body of knowledge with high u...

Full description

Saved in:
Bibliographic Details
Published in:Journal of commercial biotechnology 2011-02, Vol.17 (1), p.45-52
Main Authors: Mola, Ernesto L, Buxadó, José A, Herrera, Luis
Format: Article
Language:English
Subjects:
Amputation
Biotechnology
Business and Management
Care and treatment
Case Study
Cell growth
Cellulitis
Clinical trials
Commercialization
Costs
Diabetes
Diabetic foot
Epidermal growth factor
Experiments
Foot diseases
Health aspects
Infections
Intellectual property
Intervention
Ischemia
Leg ulcers
Manufacturing
Medical research
Patients
Pharmaceutical industry
Regulatory approval
Strategic management
Studies
Ulcers
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This article deals with repurposing of the epidermal growth factor (EGF) to the treatment of diabetic foot ulcers (DFU) grades III and IV, according to the Wagner scale. The design of a repurposing commercial strategy is described in this document as a contribution to a body of knowledge with high uncertainty and lack of methodology for decision-makers. An analysis of the potential market suggested a significant impact of the product Heberprot-P ® on costs associated to DFU treatment. Unexpected findings, obtained from a study of the competence, are reported here. The feasibility of a repurposing strategy containing short-, medium- and long-term action plans, without mutual interferences, and adopting strategic intent, strategic assessment and strategic choice as fundamental concepts is demonstrated in this work.
ISSN:1462-8732
1478-565X
DOI:10.1057/jcb.2010.28